Amal Acheche
Sousse, 4002, Tunisia
NCT Number: NCT03853174
Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020[1]. COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversable[2].
Looking for future studies?
Notify Me40 year–75 year
Male
Interventional
Not applicable
Sousse, 4002, Tunisia
Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020. COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversable.Not only the long-term exposition to noxious particles and gases contributes to the development of COPD, but also so many others factors such as genetics and cigarette smoking. It has been shown that cigarettes are harmful and contributed to different extra pulmonary disorders. Indeed, it induced a systemic inflammation that was considered as a key process in the pathogenesis of COPD and triggered the activation of inflammatory cells and an abnormal increase of circulating cytokines such as CRP, interleukin (IL6), IL8, tumor necrosis factor alpha (TNF alpha) and leptin.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Endurance training were prformed. Intensity was gradually increased.
Resistance training were prformed. Intensity was gradually increased.
Time frame: Baseline, 6 months
The interleukines were determined by ELISA assays with commercial kits
Faculty of Medicine, Sousse
Other
Effect of Exercise Training on Inflammatory Mediators in COPD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00655993
COPD, Chronic Disease
Loma Linda, California, United States
View Trial DetailsNCT00677560
Asthma, Bronchial Diseases
London, United Kingdom
View Trial DetailsNCT00147017
Bronchial Diseases, Bronchitis
London, United Kingdom
View Trial DetailsNCT04105075
Body Weight, COPD
Voronezh, Russia
View Trial Details